Awaiting development: Guidance and quality standards

Showing 61 to 70 of 86

Guidance and quality standards awaiting development
Title	Type
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]	Technology appraisal guidance
Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]	Technology appraisal guidance
Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741]	Technology appraisal guidance
Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]	Technology appraisal guidance
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]	Technology appraisal guidance